Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 8/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.39 |
| ▸ | CDK2 | P24941 | 3/20 | 0.39 |
| ▸ | FLT3 | P36888 | 2/20 | 0.37 |
| ▸ | AXL | P30530 | 3/20 | 0.34 |
| ▸ | TYRO3 | Q06418 | 3/20 | 0.34 |
| ▸ | MERTK | Q12866 | 3/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.34 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.33 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.33 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3704450 | 0.89 | TTK (0.35) | TTKCCNA2CDK2FLT3FGFR3 | |
| SCHEMBL3699631 | 0.78 | CHEK1 (0.34) | TTKCCNA2CDK2TYRO3CHEK1 | |
| SCHEMBL3704373 | 0.76 | IRAK4 (0.35) | TTKCCNA2CDK2FLT3CHEK1 | |
| SCHEMBL5538647 | 0.74 | SCD (0.37) | TTKCCNA2CDK2JAK2JAK3 | |
| SCHEMBL3709135 | 0.73 | TTK (0.35) | TTKCCNA2CDK2AXLTYRO3 | |
| SCHEMBL3703694 | 0.72 | CHEK1 (0.34) | TTKCCNA2CDK2TYRO3CHEK1 | |
| SCHEMBL3706768 | 0.72 | PSEN1 (0.36) | TTKCCNA2CDK2AXLTYRO3 | |
| SCHEMBL3706764 | 0.72 | PSEN1 (0.36) | TTKCCNA2CDK2AXLTYRO3 | |
| SCHEMBL3703452 | 0.71 | CHEK1 (0.32) | TTKCCNA2CDK2CHEK1KCNH2 | |
| SCHEMBL3702547 | 0.68 | CHEK1 (0.34) | TTKCCNA2CDK2AXLTYRO3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122843-A1 | Compounds and Their Use for Treatment of Amyloid Beta-Related Diseases | ASTRAZENECA AB (SE) | 2012-05-17 | — | — | US | disclosed |
| US-20120122843-A1 | Compounds and Their Use for Treatment of Amyloid Beta-Related Diseases | ASTRAZENECA AB (SE) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122843-A1 | Compounds and Their Use for Treatment of Amyloid Beta-Related Diseases | APP, BACE1, PSEN1 | TTK 4669/4885CCNA2 4448/4885CDK2 4588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.